Zealand Pharma A/S
CSE:ZEAL
Zealand Pharma A/S
Intangible Assets
Zealand Pharma A/S
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Intangible Assets
kr12.6m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Intangible Assets
kr12.3B
|
CAGR 3-Years
265%
|
CAGR 5-Years
92%
|
CAGR 10-Years
70%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Intangible Assets
€4m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Intangible Assets
kr6.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
50%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Intangible Assets
kr276k
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
3%
|
|
|
Saniona AB
STO:SANION
|
Intangible Assets
kr4.8m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Zealand Pharma A/S
Glance View
Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.
See Also
What is Zealand Pharma A/S's Intangible Assets?
Intangible Assets
12.6m
DKK
Based on the financial report for Dec 31, 2024, Zealand Pharma A/S's Intangible Assets amounts to 12.6m DKK.
What is Zealand Pharma A/S's Intangible Assets growth rate?
Intangible Assets CAGR 5Y
38%
Over the last year, the Intangible Assets growth was 3%. The average annual Intangible Assets growth rates for Zealand Pharma A/S have been -38% over the past three years , 38% over the past five years .
You don't have any saved screeners yet